Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatments & Surgery
Share your love
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
How CU’s ‘Transformative’ Glaucoma Fellowship Prepared Ophthalmologist for Future Career – CU Anschutz newsroom
How CU’s ‘Transformative’ Glaucoma Fellowship Prepared Ophthalmologist for Future Career CU Anschutz newsroom Source: Author: | Date: 2025-07-03 07:00:00 Source: Author: | Date: 2025-07-03 07:00:00
Nick Mamalis, MD, Gives Advice on Teaching Cataract Surgery – School of Medicine | University of Utah
Nick Mamalis, MD, Gives Advice on Teaching Cataract Surgery School of Medicine | University of Utah Source: Author: | Date: 2025-05-21 07:00:00 Source: Author: | Date: 2025-05-21 07:00:00
Kuldev Singh, MD, MPH, on Cataract Coach – Stanford Medicine
Kuldev Singh, MD, MPH, on Cataract Coach Stanford Medicine Source: Author: | Date: 2025-04-10 06:29:00 Source: Author: | Date: 2025-04-10 06:29:00
New research uncovers promising treatment for neurodegenerative diseases like ALS, glaucoma | Ophthalmology – Stanford Medicine
New research uncovers promising treatment for neurodegenerative diseases like ALS, glaucoma | Ophthalmology Stanford Medicine Source: Author: | Date: 2025-02-20 08:00:00 Source: Author: | Date: 2025-02-20 08:00:00
MicroPulse TLT Proven Effective for Glaucoma
Iridex Corporation, a global leader in laser-based medical systems for glaucoma and retinal disease treatment, has announced the publication of a groundbreaking peer-reviewed study in Ophthalmology Therapy. The study provides compelling evidence of the long-term safety and efficacy of MicroPulse…
Galimedix Begins Phase 2 Trial for GAL-101 in Dry AMD
Galimedix Therapeutics has announced the initiation of a phase 2 clinical study called eDREAM (NCT06659549), evaluating the efficacy and safety of GAL-101 eye drops in patients with dry age-related macular degeneration (AMD) and geographic atrophy (GA). About the Phase 2…
NEI Study Reveals Annexin-V’s Role in Retinal Diseases
A recent study led by the National Eye Institute (NEI) has revealed new insights into annexin-V, a key biomarker traditionally used to track apoptosis (programmed cell death) and retinal cell degeneration in eye diseases. Published in the International Journal of…
2023 Recap: Top 15 Research in Ophthalmology
2024 Recap is here! Click to review:Top 10 Breakthroughs in Ophthalmology Research In the fast-evolving landscape of ophthalmology research, 2023 has proven to be a pivotal year marked by groundbreaking discoveries and innovation. From revolutionary cell replacement therapies to novel…
ACELYRIN Halts Izokibep Development | OBN
ACELYRIN has announced that the Phase 2b/3 clinical trial evaluating izokibep for non-infectious, non-anterior uveitis did not achieve its primary endpoint. The trial results did not demonstrate a statistically significant improvement in time to treatment failure versus placebo. Consequently, the…